Michel David

Michel is currently responsible for CMC and Clinical Supply at NOEMA Pharma, developing new central nervous system (CNS) therapies.

He is responsible for a portfolio covering 4 molecules and 6 ongoing trials Phase 2 a & b and entry into Phase3.

Michel has over 25 years of experience in Pharmaceutical Development, Manufacturing and Supply, at Roche, Aventis and in Biotech Start-ups.

Michel is a Chemical Engineer and holds an MBA from INSEAD.